COVID-19 Pandemic Clinical Trial
Official title:
A Phase I/II Clinical Trial to Evaluate the Safety, Immunogenicity and Immune Persistence of COVID-19 mRNA Vaccine in Healthy People Aged 18 Years and Above.
Verified date | October 2022 |
Source | Stemirna Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial is a phase I/II clinical trial to evaluate the safety, immunogenicity and immune persistence of COVID-19 mRNA vaccine in healthy people aged 18 years and above.
Status | Completed |
Enrollment | 480 |
Est. completion date | November 11, 2022 |
Est. primary completion date | August 28, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - People aged 18-60 years (both inclusive) for phase 1 and aged =18 years for phase 2; - Medical history and physical examination indicating as a healthy person; - The female participant or the spouse (or partner) of the male participant in child-birthing age agrees to use effective contraceptive measure throughout the whole course of this clinical trial. - Those who are participating in this clinical trial voluntarily, have signed the informed consent form, and been able to understand and comply with the requirements of the clinical trial protocol. Exclusion Criteria: - Confirmed cases or history of SARS-CoV-2 infection; - Has a history of SARS and MERS virus infection; - Has fever (axillary temperature =37.3?), dry cough, fatigue, nasal congestion, runny nose, sore throat, myalgia, diarrhea, shortness of breath, and dyspnea within 14 days before vaccination; - Positive urine pregnancy test; - Axillary temperature =37.3? at the day vaccinated; - History of severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurosis, edema, etc.) or allergies to known components of COVID-19 mRNA vaccine; - History or family history of convulsions, epilepsy, encephalopathy, or mental illness; - Suffering from congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; - Known suffering from diseases including: acute respiratory disease (such as flu-like illness, acute cough, sore throat), severe cardiovascular disease, kidney disease, uncontrolled hypertension (systolic blood pressure >150 mmHg, diastolic blood pressure >90 mmHg), diabetes complications, malignant tumor, all sorts of acute illness or chronic diseases acute phase; - Diagnosis with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, or other autoimmune disease; - Abnormal coagulation function (such as lack of coagulation factor, coagulation disorders); - Receiving anti-tuberculosis treatment; - Long-term receipt (continuous=7 days) of glucocorticoid (reverence value for dose: amount to=20 mg/d prednisone equivalent), except inhaled, topical, nasal, aural and ophthalmic corticosteroids, within 6 months before screening; Receipt of immunotherapy or immunosuppressant within 3 months (continuous oral or infusion for more than 14 days); - Receipt of live attenuated vaccine within 28 days prior to vaccination and other vaccines within 14 days prior to vaccination; - Receipt of blood products within 3 months prior to vaccination - Receipt of other study drugs within 6 months prior to vaccination; - Receipt of any SARS-COV-2 vaccine; - Other situations judged by the investigators that are not suitable for participating in this clinical trial. |
Country | Name | City | State |
---|---|---|---|
Lao People's Democratic Republic | Mayfong Mayxay | Vientiane |
Lead Sponsor | Collaborator |
---|---|
Stemirna Therapeutics |
Lao People's Democratic Republic,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | The positive conversion rate, 2-fold or 4-fold rise and GMT/GMI of the SARS-COV-2 S-protein specific antibody (specific total antibody/IgG antibody), neutralizing antibody | The positive conversion rate, 2-fold or 4-fold rise and GMT/GMI of the SARS-COV-2 S-protein specific antibody (specific total antibody/IgG antibody), neutralizing antibody before 1st and 2nd immunization, 90, 180, 365 days after the full immunization | before 1st and 2nd immunization, 90, 180, 365 days after the full immunization | |
Other | Cellular immunity INF-?, IL-4 and IL-2 | Cellular immunity (INF-?, IL-4 and IL-2) before 1st and 2nd immunization, and 14, 90, 180, 365 days after the full immunization | before 1st and 2nd immunization, and 14, 90, 180, 365 days after the full immunization | |
Primary | local/systemic solicited adverse reaction/events | The incidence of local/systemic solicited adverse reaction/events | up to 6 days after each dose | |
Primary | unsolicited adverse events | The incidence of unsolicited adverse events | up to 21 days and up to 28 days after the first and second dose of immunization, respectively | |
Primary | The incidence of SAE | The incidence of SAE from the first dose of vaccination to 28 days after the full course of immunization | up to 28 days after the full course of immunization | |
Secondary | The seroconversion rate, 2-fold or 4-fold rise and GMT/GMI of the SARS-COV-2 S-protein specific antibody (specific total antibody/IgG antibody) and neutralizing antibody | The seroconversion rate, 2-fold or 4-fold rise and GMT/GMI of the SARS-COV-2 S-protein specific antibody (specific total antibody/IgG antibody) and neutralizing antibody 14 days after the full immunization in the subjects who take two doses as protocol specified | 14 days after the full immunization | |
Secondary | The incidence of SAE | The incidence of SAE within the 29th ~365th day after the full course of immunization | the 29th ~365th day after the full course of immunization | |
Secondary | Changes in laboratory abnormal parameters | Changes in laboratory abnormal parameters in the participants who take at least of one dose | after at least of one dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05197634 -
The Impact of Covid-19 Pandemic On The Children With Autism Spectrum Disorder
|
||
Recruiting |
NCT05918939 -
UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)
|
Early Phase 1 | |
Completed |
NCT05383560 -
Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults
|
Phase 2 | |
Active, not recruiting |
NCT05125874 -
Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization
|
N/A | |
Completed |
NCT05517148 -
Effects of an Immersive Virtual Reality Intervention Combined With Mindfulness-based Stress Reduction
|
N/A | |
Completed |
NCT05552989 -
Towards Better Preparedness for Future Catastrophes - Local Lessons-learned From COVID-19
|
||
Completed |
NCT05543551 -
Effects of Diagrammatic Breathing With and Without Resistance in Post Covid Patients on ADLs
|
N/A | |
Active, not recruiting |
NCT06272253 -
UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects
|
Early Phase 1 | |
Active, not recruiting |
NCT05585567 -
A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5
|
Early Phase 1 | |
Active, not recruiting |
NCT05582746 -
COVID-19 Testing and Vaccine Literacy for Women With Criminal Legal System Involvement
|
N/A | |
Not yet recruiting |
NCT05381883 -
Mental Health of Professionals of the Silver Economy of New Aquitaine : Online Survey of Accommodation Establishments for Old People and Home Assistance Establishments
|
N/A | |
Recruiting |
NCT05062681 -
RCT on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow
|
Phase 4 | |
Completed |
NCT04697030 -
Burnout Among Adolescent Population During Covid-19 Lockdown in Pakistan
|
||
Active, not recruiting |
NCT05419167 -
STEP-COVID: A Program for Pregnant Women During the SARS-CoV-2 Pandemic
|
Phase 1 | |
Terminated |
NCT05553964 -
SARS-CoV-2 OTC At Home Test
|
N/A | |
Completed |
NCT05596032 -
Prospective Study to Validate the Diagnostic Performance of IVD CAPSULE COVID-19-NP Test for the Detection of SARS-CoV-2
|
||
Completed |
NCT05583812 -
A Study of FB2001 for Inhalation in Healthy Chinese Adults
|
Phase 1 | |
Completed |
NCT05844410 -
Evaluation of Corticosteroids Use and Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Study
|
||
Completed |
NCT05123573 -
Self-Perceived in Medical Students Undergoing Distance Learning
|
||
Completed |
NCT05305300 -
A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals
|
Phase 1 |